mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2024-4-115-120mrj-1629Research ArticleОБЗОРЫREVIEWSВакцинопрофилактика опоясывающего лишая (Herpes zoster) у больных с иммуновоспалительными ревматическими заболеваниями: новые данныеVaccination against Herpes zoster in patients with immune-mediated inflammatory rheumatic diseases: new datahttps://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravyovaN. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522 

n-muravjeva@mail.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522 

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202421082024184115120Copyright © Муравьева Н.В., Белов Б.С., 20242024Муравьева Н.В., Белов Б.С.Muravyova N.V., Belov B.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1629

У больных с иммуновоспалительными ревматическими заболеваниями (ИВРЗ) риск развития опоясывающего лишая (Herpes zoster, HZ) выше, чем в общей популяции. Для профилактики заболевания и его осложнений доступны живая аттенуированная и инактивированная рекомбинантная адъювантная вакцины. Живая аттенуированная вакцина может быть использована у больных с ИВРЗ при соблюдении определенных условий, однако, они не всегда выполнимы. Преимуществом инактивированной рекомбинантной адъювантной вакцины является возможность ее применения на фоне антиревматической терапии. В обзоре проанализированы зарубежные исследования, касающиеся безопасности, иммуногенности и эффективности рекомбинантной адъювантной вакцины против HZ у больных с ИВРЗ. 

Patients with immune-mediated inflammatory rheumatic diseases (IIRD) are more likely to develop herpes zoster (HZ) than individuals in the general population. Live attenuated vaccines and inactivated recombinant vaccines with adjuvant are available to prevent the disease and its complications. Live attenuated vaccine can be used in patients with IIRD if certain conditions are met, although these cannot always be fulfilled. The advantage of the inactivated recombinant adjuvant vaccine is that it can be used against a background of anti-rheumatic therapy. The review analyzes foreign studies on the safety, immunogenicity and efficacy of recombinant adjuvant vaccine against HZ in patients with IIRD. 

иммуновоспалительные ревматические заболеванияревматоидный артритсистемная красная волчанкаглюкокортикоидыингибиторы Янус-киназгенно-инженерная биологическая терапияопоясывающий лишайвакцинациярекомбинантная адъювантная вакцинаimmune-inflammatory rheumatic diseasesrheumatoid arthritissystemic lupus erythematosusglucocorticoidsJanus kinase inhibitorsbiologic disease-modifying antirheumatic drugsherpes zostervaccinationrecombinant adjuvant vaccineСтатья подготовлена в рамках научно-исследовательской работы, № государственного задания 1021051503137-7.The article was prepared as part of the research work, government task №1021051503137-7.ReferencesЮщук НД, Венгеров ЮЯ, редакторы. Инфекционные болезни: национальное руководство. Москва: ГЭОТАР-Медиа; 2021.Yushchuk ND, Vengerov YuYa, editors. Infectious diseases: national guidelines. Moscow: GEOTAR-Media; 2021.Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi: 10.1177/2051013615599151.Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015 Jul;3(4):109-20. doi: 10.1177/2051013615599151.Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019 Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041. eCollection 2019.Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019 Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041. eCollection 2019.Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014 Apr;42(2): 325-34. doi: 10.1007/s15010-013-0550-8. Epub 2013 Nov 10.Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014 Apr;42(2): 325-34. doi: 10.1007/s15010-013-0550-8. Epub 2013 Nov 10.Dlamini ST, Htet KM, Theint ECC, et al. Herpes zoster risk in patients with rheumatoid arthritis and its association with medications used. Int J Environ Res Public Health. 2023 Jan 24;20(3):2123. doi: 10.3390/ijerph20032123.Dlamini ST, Htet KM, Theint ECC, et al. Herpes zoster risk in patients with rheumatoid arthritis and its association with medications used. Int J Environ Res Public Health. 2023 Jan 24;20(3):2123. doi: 10.3390/ijerph20032123.Liao TL, Lin CH, Chen HH, et al. Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients. J Am Heart Assoc. 2017 Jul 19;6(7):e006304. doi: 10.1161/JAHA.117.006304.Liao TL, Lin CH, Chen HH, et al. Significant associations of neurological complications of herpes zoster with stroke in rheumatoid arthritis patients. J Am Heart Assoc. 2017 Jul 19;6(7):e006304. doi: 10.1161/JAHA.117.006304.Nakajima A, Urano W, Inoue E, et al. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol. 2015 Jul;25(4):558-61. doi: 10.3109/14397595.2014.984829. Epub 2015 Feb 4.Nakajima A, Urano W, Inoue E, et al. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol. 2015 Jul;25(4):558-61. doi: 10.3109/14397595.2014.984829. Epub 2015 Feb 4.Yamaguchi R, Tanaka E, Nakajima A, et al. Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. Mod Rheumatol. 2022 Apr 18;32(3):522-527. doi: 10.1093/mr/roab026.Yamaguchi R, Tanaka E, Nakajima A, et al. Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids. Mod Rheumatol. 2022 Apr 18;32(3):522-527. doi: 10.1093/mr/roab026.Zhang N, Wilkinson S, Riaz M, et al. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol. 2012 Nov-Dec; 30(6):962-71. Epub 2012 Dec 17.Zhang N, Wilkinson S, Riaz M, et al. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol. 2012 Nov-Dec; 30(6):962-71. Epub 2012 Dec 17.Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006 Nov;45(11): 1370-5. doi: 10.1093/rheumatology/kel328. Epub 2006 Sep 26.Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006 Nov;45(11): 1370-5. doi: 10.1093/rheumatology/kel328. Epub 2006 Sep 26.Mok CC, Ho LY, Tse SM, et al. Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies. Clin Rheumatol. 2023 Apr;42(4):1019-1026. doi: 10.1007/s10067-022-06450-2. Epub 2022 Nov 16.Mok CC, Ho LY, Tse SM, et al. Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies. Clin Rheumatol. 2023 Apr;42(4):1019-1026. doi: 10.1007/s10067-022-06450-2. Epub 2022 Nov 16.Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014 May; 81(3):215-21. doi: 10.1016/j.jbspin.2013.07.009. Epub 2013 Aug 7.Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014 May; 81(3):215-21. doi: 10.1016/j.jbspin.2013.07.009. Epub 2013 Aug 7.Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022 Jan;81(1):41-47. doi: 10.1136/annrheumdis2021-220651. Epub 2021 Jul 28.Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022 Jan;81(1):41-47. doi: 10.1136/annrheumdis2021-220651. Epub 2021 Jul 28.Atzeni F, Gozza F, Riva A, et al. Conventional, biological disease-modifying antirheumatic drugs and Janus kinase inhibitors and varicella zoster virus. Expert Opin Pharmacother. 2023 Apr;24(6):679-689. doi: 10.1080/14656566.2023.2195050. Epub 2023 Mar 28.Atzeni F, Gozza F, Riva A, et al. Conventional, biological disease-modifying antirheumatic drugs and Janus kinase inhibitors and varicella zoster virus. Expert Opin Pharmacother. 2023 Apr;24(6):679-689. doi: 10.1080/14656566.2023.2195050. Epub 2023 Mar 28.Sakai R, Kasai S, Hirano F, et al. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. Int J Rheum Dis. 2018 Sep;21(9):1670-1677. doi: 10.1111/1756-185X.13300. Epub 2018 Apr 17.Sakai R, Kasai S, Hirano F, et al. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. Int J Rheum Dis. 2018 Sep;21(9):1670-1677. doi: 10.1111/1756-185X.13300. Epub 2018 Apr 17.Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1843-7. doi: 10.1136/annrheumdis2016-209131. Epub 2016 Apr 25.Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Oct; 75(10):1843-7. doi: 10.1136/annrheumdis2016-209131. Epub 2016 Apr 25.Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol. 2022 Sep 23:13:996662. doi: 10.3389/fimmu.2022.996662. eCollection 2022.Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol. 2022 Sep 23:13:996662. doi: 10.3389/fimmu.2022.996662. eCollection 2022.Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi: 10.1093/rheumatology/kez087.Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Oct 1;58(10):1755-1766. doi: 10.1093/rheumatology/kez087.Sanchez Gonzalez CO, Nieto Gonzalez JC. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. Reumatol Clin (Engl Ed). 2022 Oct;18(8): 453-458. doi: 10.1016/j.reumae.2021.06.001. Epub 2021 Dec 8.Sanchez Gonzalez CO, Nieto Gonzalez JC. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. Reumatol Clin (Engl Ed). 2022 Oct;18(8): 453-458. doi: 10.1016/j.reumae.2021.06.001. Epub 2021 Dec 8.Alves C, Penedones A, Mendes D, Marques FB. The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2022 Mar 1;28(2):e407-e414. doi: 10.1097/RHU.0000000000001749.Alves C, Penedones A, Mendes D, Marques FB. The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2022 Mar 1;28(2):e407-e414. doi: 10.1097/RHU.0000000000001749.Gialouri CG, Moustafa S, Thomas K, et al. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and realworld studies. Rheumatol Int. 2023 Mar;43(3): 421-435. doi: 10.1007/s00296-022-05270-6. Epub 2023 Jan 13.Gialouri CG, Moustafa S, Thomas K, et al. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and realworld studies. Rheumatol Int. 2023 Mar;43(3): 421-435. doi: 10.1007/s00296-022-05270-6. Epub 2023 Jan 13.Koh JH, Lee J, Kim SH, et al. Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. 2018 Apr; 45(4):465-469. doi: 10.3899/jrheum.170936. Epub 2018 Feb 1.Koh JH, Lee J, Kim SH, et al. Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol. 2018 Apr; 45(4):465-469. doi: 10.3899/jrheum.170936. Epub 2018 Feb 1.Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012 Jul 4;308(1):43-9. doi: 10.1001/jama.2012.7304.Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012 Jul 4;308(1):43-9. doi: 10.1001/jama.2012.7304.Calabrese LH, Abud Mendoza C, Stephen M, et al. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken). 2020 Mar;72(3):353-359. doi: 10.1002/acr.24010.Calabrese LH, Abud Mendoza C, Stephen M, et al. Live zoster vaccine in patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, or adalimumab with methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken). 2020 Mar;72(3):353-359. doi: 10.1002/acr.24010.Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017 Jul; 44(7):1083-1087. doi: 10.3899/jrheum.160685. Epub 2017 Mar 15.Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017 Jul; 44(7):1083-1087. doi: 10.3899/jrheum.160685. Epub 2017 Mar 15.Eberhardson M, Hall S, Papp KA, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis. 2017 Oct 1;65(7): 1174-1182. doi: 10.1093/cid/cix484.Eberhardson M, Hall S, Papp KA, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis. 2017 Oct 1;65(7): 1174-1182. doi: 10.1093/cid/cix484.Venerito V, Stefanizzi P, Cantarini L, et al. Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study. Int J Mol Sci. 2023 Apr 9; 24(8):6967. doi: 10.3390/ijms24086967.Venerito V, Stefanizzi P, Cantarini L, et al. Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study. Int J Mol Sci. 2023 Apr 9; 24(8):6967. doi: 10.3390/ijms24086967.Esteban-Vazquez A, Steiner M, Castaсeda E, et al. The real-world study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase inhibitors. Vaccines (Basel). 2023 Oct 18;11(10): 1610. doi: 10.3390/vaccines11101610.Esteban-Vazquez A, Steiner M, Castaсeda E, et al. The real-world study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase inhibitors. Vaccines (Basel). 2023 Oct 18;11(10): 1610. doi: 10.3390/vaccines11101610.Källmark H, Bergström T, Nagel J, et al. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford). 2024 Jul 1; 63(7):2024-2033. doi: 10.1093/rheumatology/kead552.Källmark H, Bergström T, Nagel J, et al. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford). 2024 Jul 1; 63(7):2024-2033. doi: 10.1093/rheumatology/kead552.Kojima S, Iwamoto T, Kobayashi Y, et al. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs. RMD Open. 2024 Feb 21;10(1): e003902. doi: 10.1136/rmdopen-2023-003902.Kojima S, Iwamoto T, Kobayashi Y, et al. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs. RMD Open. 2024 Feb 21;10(1): e003902. doi: 10.1136/rmdopen-2023-003902.Andreica I, Reale S, Intini G, et al. Tolerability and safety of recombinant zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases – a prospective longitudinal study over 6 months. Ann Rheum Dis. 2023;82(suppl. 1):550. doi: 10.1136/annrheumdis-2023-eular.2827.Andreica I, Reale S, Intini G, et al. Tolerability and safety of recombinant zoster vaccine in patients with inflammatory rheumatic musculoskeletal diseases – a prospective longitudinal study over 6 months. Ann Rheum Dis. 2023;82(suppl. 1):550. doi: 10.1136/annrheumdis-2023-eular.2827.Stevens E, Weinblatt ME, Massarotti E, et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients. ACR Open Rheumatol. 2020 Jun;2(6):357-361. doi: 10.1002/acr2.11150. Epub 2020 May 15.Stevens E, Weinblatt ME, Massarotti E, et al. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients. ACR Open Rheumatol. 2020 Jun;2(6):357-361. doi: 10.1002/acr2.11150. Epub 2020 May 15.Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021 Nov 3;60(11):5149-5157. doi: 10.1093/rheumatology/keab139.Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021 Nov 3;60(11):5149-5157. doi: 10.1093/rheumatology/keab139.Gupta S, Arasaratnam RJ, Solow EB, Bajaj P. A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease. J Clin Rheumatol. 2022 Mar 1;28(2):e528-e531. doi: 10.1097/RHU.0000000000001790.Gupta S, Arasaratnam RJ, Solow EB, Bajaj P. A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease. J Clin Rheumatol. 2022 Mar 1;28(2):e528-e531. doi: 10.1097/RHU.0000000000001790.Pons-Bas A, Rosas J, Pons-Canet L, et al. Safety of the recombinant herpes zoster vaccine in patients with rheumatoid arthritis treated with JAKI drugs. Ann Rheum Dis. 2023;82(suppl. 1):2121. doi: 10.1136/annrheumdis-2023-eular.1013.Pons-Bas A, Rosas J, Pons-Canet L, et al. Safety of the recombinant herpes zoster vaccine in patients with rheumatoid arthritis treated with JAKI drugs. Ann Rheum Dis. 2023;82(suppl. 1):2121. doi: 10.1136/annrheumdis-2023-eular.1013.Winthrop K, Klaff J, Liu Y, et al. Evaluation of response to adjuvant recombinant zoster vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a randomized trial sub-study. Ann Rheum Dis. 2023;82(suppl. 1):148. doi: 10.1136/annrheumdis-2023-eular.2386.Winthrop K, Klaff J, Liu Y, et al. Evaluation of response to adjuvant recombinant zoster vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a randomized trial sub-study. Ann Rheum Dis. 2023;82(suppl. 1):148. doi: 10.1136/annrheumdis-2023-eular.2386.Heineman TC, Cunningham A and Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019 Aug:59:42-48. doi: 10.1016/j.coi.2019.02.009. Epub 2019 Apr 17.Heineman TC, Cunningham A and Levin M. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine. Curr Opin Immunol. 2019 Aug:59:42-48. doi: 10.1016/j.coi.2019.02.009. Epub 2019 Apr 17.Sieiro Santos C, Lopez Robles A, Alvarez Castro C, et al. Immune responses to vaccination against herpes zoster (HZ) in patients with rheumatic diseases under treatment with JAK-inhibitors: our preliminary results. Ann Rheum Dis. 2023;82(suppl. 1):1186. doi: 10.1136/annrheumdis-2023-eular.998.Sieiro Santos C, Lopez Robles A, Alvarez Castro C, et al. Immune responses to vaccination against herpes zoster (HZ) in patients with rheumatic diseases under treatment with JAK-inhibitors: our preliminary results. Ann Rheum Dis. 2023;82(suppl. 1):1186. doi: 10.1136/annrheumdis-2023-eular.998.Mas Sanchez L, Munoz Martinez P, Grau Garcia E, et al. Experience in real-world conditions of the effectiveness of the vaccine against herpes zoster. Ann Rheum Dis. 2023; 82(suppl. 1):2027. doi: 10.1136/annrheumdis2023-eular.4258.Mas Sanchez L, Munoz Martinez P, Grau Garcia E, et al. Experience in real-world conditions of the effectiveness of the vaccine against herpes zoster. Ann Rheum Dis. 2023; 82(suppl. 1):2027. doi: 10.1136/annrheumdis2023-eular.4258.Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023 Mar;75(3):333-348. doi: 10.1002/art.42386. Epub 2023 Jan 4.Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023 Mar;75(3):333-348. doi: 10.1002/art.42386. Epub 2023 Jan 4.Pier M, Wolbink G, Boekel L. Time to talk to adults with rheumatic diseases about herpes zoster vaccination. Lancet Rheumatol. 2024 Apr;6(4):e247-e251. doi: 10.1016/S2665-9913(24)00019-5. Epub 2024 Feb 16.Pier M, Wolbink G, Boekel L. Time to talk to adults with rheumatic diseases about herpes zoster vaccination. Lancet Rheumatol. 2024 Apr;6(4):e247-e251. doi: 10.1016/S2665-9913(24)00019-5. Epub 2024 Feb 16.

The authors declare that there are no conflicts of interest present.